Literature DB >> 11835313

Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis.

Patricia Murphy1, Anthony Sharp, Joseph Shin, Vitaliy Gavrilyuk, Cinzia Dello Russo, Guy Weinberg, Frank R Sharp, Aigang Lu, Michael T Heneka, Douglas L Feinstein.   

Abstract

The production of nitric oxide by the inflammatory isoform of nitric oxide synthase (NOS2) in brain glial cells is thought to contribute to the causes and development of neurological diseases and trauma. We previously demonstrated that activation of a heat shock response (HSR) by hyperthermia reduced NOS2 expression in vitro, and in vivo attenuated the clinical and histological symptoms of the demyelinating disease experimental autoimmune encephalomyelitis (EAE; Heneka et al. [2001] J. Neurochem. 77:568-579). Benzoquinoid ansamycins are fungal-derived antibiotics with tyrosine kinase inhibitory properties, and which also induce a HSR by allowing activation of HS transcription factor HSF1. We now show that two members of this class of drugs (geldanamycin and 17-allylamino-17-demethoxygeldanamycin) also induce a HSR in primary rat astrocytes and rat C6 glioma cells. Both drugs dose-dependently reduced nitrite accumulation, NOS2 steady-state mRNA levels, and the cytokine-dependent activation of a rat 2.2-kB NOS2 promoter construct stably expressed in C6 cells. These inhibitory effects were partially reversed by quercetin, a bioflavonoid which prevents HSF1 binding to DNA and thus attenuates the HSR. Ansamycins increased mRNA levels of the inhibitory IkappaBalpha protein, suggesting that inhibition of NFkappaB activation could contribute to their suppressive effects. Finally, in C57BL/6 mice actively immunized to develop EAE, a single injection of geldanamycin at 3 days after immunization reduced disease onset by over 50%. These results indicate that ansamycins can exert potent anti-inflammatory effects on brain glial cells which may provide therapeutic benefit in neuroinflammatory diseases. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835313     DOI: 10.1002/jnr.10139

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

Review 1.  Autoimmune modulation of astrocyte-mediated homeostasis.

Authors:  Thomas Korn; Mahendra Rao; Tim Magnus
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70.

Authors:  Marybeth Howard; Jérémie Roux; Hyon Lee; Byron Miyazawa; Jae-Woo Lee; Brandi Gartland; Amanda J Howard; Michael A Matthay; Michel Carles; Jean-François Pittet
Journal:  Thorax       Date:  2010-04       Impact factor: 9.139

Review 3.  Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies.

Authors:  Stefan Tukaj; Grzegorz Węgrzyn
Journal:  Cell Stress Chaperones       Date:  2016-01-20       Impact factor: 3.667

Review 4.  Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.

Authors:  Masahiro Waza; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2006-06-02       Impact factor: 4.599

5.  The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.

Authors:  Lucia Lisi; Susan McGuire; Anthony Sharp; Gabriela Chiosis; Pierluigi Navarra; Douglas L Feinstein; Cinzia Dello Russo
Journal:  J Neuroimmunol       Date:  2012-11-02       Impact factor: 3.478

Review 6.  To fold or not to fold: modulation and consequences of Hsp90 inhibition.

Authors:  Laura B Peterson; Brian S J Blagg
Journal:  Future Med Chem       Date:  2009-05       Impact factor: 3.808

7.  Network pharmacology identify intersection genes of quercetin and Alzheimer's disease as potential therapeutic targets.

Authors:  Caihui Wei; Shu Li; Yu Zhu; Wenzhi Chen; Cheng Li; Renshi Xu
Journal:  Front Aging Neurosci       Date:  2022-08-23       Impact factor: 5.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.